Atrium Therapeutics Unveils Promising Data on ATR 1072 for Treating PRKAG2 Syndrome#USA#Chicago#Atrium_Therapeutics#PRKAG2_Syndrome#ATR_1072
Atrium Therapeutics Unveils Promising Data on ATR 1072 for Treating PRKAG2 Syndrome
Atrium Therapeutics has announced new findings on ATR 1072 that may offer hope for patients with PRKAG2 syndrome, demonstrating reversal of disease features.
third-news.com
November 2, 2026 at 11:47 AM
Atrium Therapeutics Unveils Promising Data on ATR 1072 for Treating PRKAG2 Syndrome#USA#Chicago#Atrium_Therapeutics#PRKAG2_Syndrome#ATR_1072
Atrium Therapeutics Launches Groundbreaking Corventis Clinical Trial Aimed at PRKAG2 Syndrome#None#San_Diego#Atrium_Therapeutics#PRKAG2_Syndrome#ATR_1072
Atrium Therapeutics Launches Groundbreaking Corventis Clinical Trial Aimed at PRKAG2 Syndrome
Atrium Therapeutics has initiated the Corventis trial, the first to assess a treatment for PRKAG2 syndrome, marking a significant milestone in cardiomyopathy research.
third-news.com
October 27, 2026 at 10:47 AM
Atrium Therapeutics Launches Groundbreaking Corventis Clinical Trial Aimed at PRKAG2 Syndrome#None#San_Diego#Atrium_Therapeutics#PRKAG2_Syndrome#ATR_1072
Atrium Therapeutics Shows Promising Progress with Second Quarter 2026 Financial Results#USA#San_Diego#BMS#Atrium_Therapeutics#ATR_1072
Atrium Therapeutics Shows Promising Progress with Second Quarter 2026 Financial Results
Atrium Therapeutics has reported its financial results for Q2 2026, highlighting FDA approval of ATR 1072 and collaboration milestones with BMS.
third-news.com
August 13, 2026 at 8:50 PM
Atrium Therapeutics Shows Promising Progress with Second Quarter 2026 Financial Results#USA#San_Diego#BMS#Atrium_Therapeutics#ATR_1072